Month: November 2023

Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy USA – English 

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (‘Calliditas’) today announced that its partner Everest Medicines (HKEX: 1952.HK) (‘Everest’) announced that China’s National Medical Products Administration (NMPA) has approved Nefecon® for the treatment of primary immunoglobulin A…